Ji, L., Ma, J., Li, H., et al. (2014) Dapagliflozin as Monotherapy in Drug-Naive Asian Patients with Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study. Clinical Therapeutics, 36, 84-100.
https://doi.org/10.1016/j.clinthera.2013.11.002

has been cited by the following article:

• TITLE: Meta-Analysis on Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus

  AUTHORS: Lili She, Hongyan Wu

  KEYWORDS: Dapagliflozin, Type 2 Diabetes Mellitus, Randomized Controlled Trial, Meta-Analysis

  JOURNAL NAME: Yangtze Medicine, Vol.2 No.3, August 30, 2018

  ABSTRACT: Objective: To evaluate the safety of dapagliflozin for Type 2 Diabetes Mellitus (T2DM). Methods: A systematic search of Pubmed, Embase, Cochrance Library, Web of Science, CNKI, Wanfang Data and VIP database for randomized controlled trials (RCTs) comparing dapagliflozin with placebo was performed up to February 2018. The index words included dapagliflozin, type 2 diabetes mellitus and randomized controlled trial. Results: A total of 19 RCTs involving 7704 participants were incorporated into the study. Compared with placebo, dapagliflozin did not increase the risk of hypoglycemia [OR = 1.14, 95%CI (0.95, 1.36), P = 0.17] and hypotension [OR = 1.43, 95%CI (0.94, 2.17), P = 0.10], but significantly increased the incidences of renal adverse events [OR = 1.57, 95%CI (1.17, 2.09), P = 0.002], genital tract infection [OR = 3.65, 95%CI (2.93, 4.56), P Conclusions: Generally, dapagliflozin had no risk of hypoglycemia and hypotension in patients with T2DM, but there were risks of renal adverse events and urogenital tract infection. Due to the limitations of this study, larger samples and RCTs with long-term follow-up are needed for further verification.